Literature DB >> 32169625

Ringing bells: Morganella morganii fights for recognition.

Altaf Bandy1.   

Abstract

OBJECTIVES: The global increase in rare opportunistic microbial infections is alarming. The current review was undertaken to study the diversified disease spectrum, pathogenicity, and resistance patterns of Morganella morganii. STUDY
DESIGN: This study is a review of the diversified disease spectrum of M. morganii.
METHODS: The articles used in this review were all extracted from PubMed and Google Scholar, using the terms 'M. morganii', 'prevalence', 'virulence factors', 'infections', 'resistance pattern', and 'genomics'. This review includes original articles, reviews, and case reports focusing on M. morganii, hospital-based prevalence studies, and studies on resistance in M. morganii published between 1906 and April 2019. Articles published in English, French, Spanish, and Chinese were reviewed.
RESULTS: M. morganii has had a significant impact as a clinical pathogen and the pace of its occurrence and the increase in its resistance rates puts this bacterium on the path to becoming the next 'superbug'. These developments not only impact M. morganii, but as a result of gene and plasmid transfer evolution, other clinical pathogens have been able to acquire their diverse intrinsic and acquired virulence genes. Its vast host range raises concerns around its capacity to generate new infections through novel symbiotic relationships.
CONCLUSIONS: M. morganii opportunism is being increasingly reported across the globe. This bacterium is accumulating intrinsic and acquired multidrug resistance genes, resulting in increased morbidity and mortality rates for M. morganii infections and complicating its treatment. M. morganii should be recognized as a clinically significant pathogen, and clinicians should place this microorganism in the list of causative possibilities during patient care. It is important for both the infection control activities in hospitals and in public health sector.
Copyright © 2020 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Commensal; IncN plasmid; Microbial surveillance; Multidrug resistance; Taxonomy

Year:  2020        PMID: 32169625     DOI: 10.1016/j.puhe.2020.01.016

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  6 in total

1.  Morganella morganii, an Emerging Cause of Bloodstream Infections.

Authors:  Kevin B Laupland; David L Paterson; Felicity Edwards; Adam G Stewart; Patrick N A Harris
Journal:  Microbiol Spectr       Date:  2022-04-25

2.  Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections?

Authors:  Jyoti Chhibber-Goel; Sreehari Gopinathan; Amit Sharma
Journal:  Gut Pathog       Date:  2021-02-25       Impact factor: 5.324

Review 3.  Postvitrectomy endophthalmitis caused by Morganella morganii: a case report and literature review.

Authors:  Chung-Ting Wang; Yin-Hsi Chang; Kuan-Jen Chen; Hung-Da Chou
Journal:  BMC Infect Dis       Date:  2022-03-18       Impact factor: 3.090

4.  Morganella morganii: An unusual analysis of 11 cases of pediatric urinary tract infections.

Authors:  Huixuan Shi; Xianrui Chen; Yonghua Yao; Jinping Xu
Journal:  J Clin Lab Anal       Date:  2022-03-29       Impact factor: 3.124

5.  Metagenomic Changes of Gut Microbiota following Treatment of Helicobacter pylori Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or Lactobacillus reuteri.

Authors:  Maria Pina Dore; Rosangela Sau; Caterina Niolu; Marcello Abbondio; Alessandro Tanca; Stefano Bibbò; Mariafrancesca Loria; Giovanni Mario Pes; Sergio Uzzau
Journal:  Nutrients       Date:  2022-07-06       Impact factor: 6.706

6.  Diversity in the swimming motility and flagellar regulon structure of uropathogenic Morganella morganii strains.

Authors:  Leyla Minnullina; Zarina Kostennikova; Vladimir Evtugin; Yaw Akosah; Margarita Sharipova; Ayslu Mardanova
Journal:  Int Microbiol       Date:  2021-08-07       Impact factor: 2.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.